Shanghai Medicilon Inc.

Equities

688202

CNE100003NQ8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
37.64 CNY -5.90% Intraday chart for Shanghai Medicilon Inc. +6.45% -44.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023. CI
China Healthcare Stocks Rally on Hopes for Government Support DJ
Medicilon Appoints Dr. Qingcong Lin as President of Medicilon Usa Corp CI
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit CI
Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023. CI
Shanghai Medicilon Inc.(SHSE:688202) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Shanghai Medicilon Inc. announces an Equity Buyback for CNY 40 million worth of its shares. CI
Shanghai Medicilon Inc. authorizes a Buyback Plan. CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shanghai Medicilon Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Fosun Health Capital Reaches Cooperation Agreement with Medicilon to Explore Innovative Drug Research and Development Together CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Medicilon Logs 28.6% Jump in 2022 Profit MT
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shanghai Medicilon Gets Securities Regulator's Nod to Issue Stocks MT
Certain A Shares of Shanghai Medicilon Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2022. CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shanghai Medicilon Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shanghai Medicilon Inc. announced that it expects to receive CNY 2.16 billion in funding CI
Shanghai Medicilon Inc.(SHSE:688202) added to Shanghai Stock Exchange Health Care Sector Index CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Shanghai Medicilon Inc.
More charts
Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
37.64
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688202 Stock
  4. News Shanghai Medicilon Inc.
  5. Shanghai Medicilon Gets Securities Regulator's Nod to Issue Stocks
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW